Cointime

Stablix

company

About

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS).

  • 101 - 250

Highlights

Total Funding Amount
$63M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$63M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2021
Number Of Employee
101 - 250
Operating Status
Active

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$63M
Stablix has raised a total of $63M in funding over 2 rounds. Their latest funding was raised on Jun 3, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 3, 2021 Series A $63M 1 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Stablix is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Yes Series A
Cointime
Содержание
компания